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Abstract
Cofactors—i.e., metal ions and coenzymes—extend the catalytic scope of
enzymes and might have been among the first biological catalysts. They may
be expected to efficiently extend the catalytic potential of antibodies. Mon-
oclonal antibodies (MAbs) against Nα- p h o s p h o p y r i d o x y l -L-lysine were
s c reened for 1) binding of 5′-phosphopyridoxyl amino acids, 2) binding of
the planar Schiff base of pyridoxal-5′-phosphate (PLP) and amino acids, the
first intermediate of all PLP-dependent reactions, and 3) catalysis of the PLP-
dependent α, β-elimination reaction with β- c h l o ro -D/L-alanine. A n t i b o d y
15A9 fulfilled all criteria and was also found to catalyze the cofactor-
dependent transamination reaction of hydrophobic D-amino acids and oxo
acids (k′c a t = 0.42 min– 1 with D-alanine at 25°C). No other reactions with either
D- or L-amino acids were detected. PLP markedly contributes to catalytic
e fficacy—it is a 104 times more efficient acceptor of the amino group than
p y ruvate. The antibody ensures reaction specificity, stere o s p e c i f i c i t y, and
substrate specificity, and further accelerates the transamination re a c t i o n
(k′c a t ( A b )/k′c a t ( P L P ) = 5 × 1 03). The successive screening steps simulate the selec-
tion criteria that might have been operative in the evolution of pro t e i n -
assisted pyridoxal catalysis.
Index Entries: Catalytic antibodies; pyridoxal-5′-phosphate; trans-
a m i n a t i o n .
P y r i d o x a l - 5′-phosphate (PLP) is one of the most versatile pro s t h e t i c
g roups of enzymes. PLP-dependent enzymes catalyze a great variety of
reactions that synthesize, degrade, or interconvert amino acids ( 1 ). The
reactions include transamination, racemization, α and β d e c a r b o x y l a t i o n ,
aldol cleavage, and β and γ elimination and replacement reactions. The
PLP-dependent enzymes are of multiple evolutionary origin, belonging to
at least five independent evolutionary lineages of homologous pro t e i n s
( 2 , 3 ). Among the five independent lineages of PLP-dependent enzymes,
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the α/γ superfamily is by far the largest. The member enzymes of this
superfamily catalyze many highly diverse reactions of amino acids,
although they originate from a common ancestor and possess a similar
fold of the polypeptide chain. We generated PLP-dependent catalytic anti-
bodies in an effort to experimentally simulate the molecular evolution of
PLP-dependent enzymes. The incorporation of cofactors has been pro-
posed as a possible strategy to expand the catalytic scope of antibodies ( 4 ).
Without exception, the PLP-dependent enzymes that act on amino-
acid substrates share important mechanistic features, despite the multi-
tude of diff e rent reactions that they catalyze. All PLP-dependent enzymes
bind the coenzyme covalently through an imine linkage to the ε- a m i n o
g roup of an active-site lysine residue (“internal” aldimine). Invariably, the
first step in their reaction with an amino-acid substrate is a transamina-
tion replacing the ε-amino group with the α-amino group of the incoming
substrate amino acid. The ensuing “external” aldimine intermediate 3 f o r m s
an extended planar system of conjugated double bonds (s e e Fig. 1). The
positively charged pyridine ring acts as an electron sink, withdrawing elec-
t rons from Cα and weakening the bonds to its substituents. The pathways
of the many diff e rent reactions that are catalyzed by PLP-dependent
enzymes diverge only after the common external aldimine intermediate.
Depending on which bond is cleaved and on the subsequent covalency
changes, one specific reaction is realized. All reactions are also catalyzed
by PLP alone—the apoenzyme moiety is responsible for reaction and sub-
strate specificity as well as part of the catalytic eff i c i e n c y.
It seems almost unavoidable to assume that PLP existed before any
of the corresponding apoenzymes developed. Not a single non-PLP-depen-
dent protein has been found that seems to be evolutionarily related to a
PLP-dependent enzyme. Perhaps there existed a “cofactor-world” with
metal ions and coenzymes acting as biological catalysts before specialized
p roteins were re c ruited for this function. In a plausible hypothetical sce-
nario for the evolution of PLP-dependent enzymes, PLP reacted with a
p rotein that had to fulfill the following criteria in order to serve as a pri-
m o rdial apoenzyme: a lysine residue with adjacent binding sites for PLP
and amino-acid substrate, and a geometry of the two binding sites that
allowed formation of the planar aldimine adduct. Subsequent develop-
ment of a catalytic apparatus and its optimization for reaction and sub-
strate specificity and catalytic efficiency led to the modern PLP-dependent
enzymes ( 5 ).
Based on this interpretation of the evolutionary data, we explore d —
as substitutes for a hypothetical primordial PLP-dependent enzyme—
MAbs that were capable of binding a planar PLP-amino-acid adduct.
Antibodies elicited against Nα- ( 5′- p h o s p h o p y r i d o x y l ) -L-lysine (s e e Fig. 2)
may be assumed to comply almost ideally with the criterion for an ances-
tor PLP-enzyme—i.e., the existence of a binding site for a covalent coen-
zyme-amino-acid adduct. However, the hapten phosphopyridoxyl lysine
Applied Biochemistry and Biotechnology Vol. 83, 2000
1 8 4 G ra m a t i k ova and Christen
ABAB17.qxd  3/24/0 12:30 PM  Page 184
Applied Biochemistry and Biotechnology Vol. 83, 20001 8 5
ABAB17.qxd  3/24/0 12:31 PM  Page 185
is—in contrast to the covalent coenzyme-substrate adducts—nonplanar
owing to the reduction of the C4′- Nα double bond. As a consequence, the
antibodies elicited with phospopyridoxyl lysine may not be capable of
accommodating the planar coenzyme-substrate adduct—a feature which
is essential for the catalytic effect of PLP. This deficiency of the antigen
used for immunization was compensated by the screening protocol. The
multitude of possible transformation products of amino acids is a major
p roblem in the design of a screening pro c e d u re for PLP-dependent cat-
alytic antibodies. Because of this diff i c u l t y, we have devised a protocol that
s c reens for the occurrence of two successive crucial reaction steps rather
than for a final pro d u c t .
In a first step, the hapten-binding IgG-antibodies were screened for
binding of the planar Schiff base formed from PLP and D- or L- n o r l e u c i n e
by a competition enzyme-linked immunosorbant assay (for experimental
details, s e e ref. 7). In this ELISA, the antibodies were tested to determine
whether binding to immobilized antigen (with nonplanar phosphopyri-
d o x a l -L-lysine as hapten) was inhibited by PLP plus D- or L- n o r l e u c i n e .
Binders of the planar coenzyme-substrate aldimine adduct were assumed
to be inhibited more strongly by the conjoint effect of PLP plus amino acid
than by PLP or the amino acid alone. Antibodies 13B10, 8H4, 15A9, 11 C 2 ,
and 14G1 showed indeed that their binding to the antigen was inhibited
m o re strongly in the presence of PLP plus D- or L-norleucine than in the
p resence of PLP or the amino acid alone (s e e Fig. 3). The inhibition of anti-
body–antigen binding by the Schiff base 3 formed from PLP plus glycine
indicates the existence of a binding site for the amino-acid moiety of the
hapten, and the diff e rence in inhibition by PLP plus norleucine and PLP
plus glycine reflects the contribution of the amino-acid side chain to the
binding of the Schiff base. The inhibition profiles of antibodies 5G12 and
6E9 illustrate the binding properties of the great majority of the antibod-
ies, which did not show a significant diff e rence in the inhibition by PLP
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Fig. 2. Stru c t u re of the antigen. Nα- ( 5′- P h o s p h o p y r i d o x y l ) -L-lysine, produced by
reduction of the PLP-lysine aldimine with sodium borohydride, was coupled to maley-
lated carrier protein. For details of the experimental pro c e d u re, s e e refs. 6 and 7.
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and by PLP plus amino acids. A p p a re n t l y, these antibodies cannot accom-
modate the planar aldimine adduct in their binding site. The antibodies
d i ffer from PLP enzymes by their lack of a lysine residue at the coenzyme-
binding site. Because of the merely noncovalent binding of PLP to the anti-
bodies, the external aldimine intermediate has to be formed de novo rather
than by transamination (s e e Fig. 1). Experiments with nonenzymic model
systems (H. P. To b l e r, H. Gehring, and P. Christen, unpublished data;
ref. 8) and the residual activity of mutant PLP-dependent enzymes with-
out active-site lysine residue ( 9 , 1 0 ) have indicated that formation of the
coenzyme-substrate aldimine by transamination rather than de novo for-
mation from PLP and amino acid is not essential for catalysis. The ubiq-
uitous occurrence of the coenzyme-binding lysine residue might reflect a
historic trait rather than a mechanistic necessity ( 2 , 5 ).
In the second screening step, the aldimine-binding antibodies were
s c reened for a catalytic effect—i.e., the cleavage of the Cα-H bond of the
substrate moiety. In the molecular evolution of PLP-dependent enzymes,
the analogous step after acquiring the capacity of aldimine binding may
be assumed to have been the development of a catalytic apparatus facili-
tating the cleavage of one of the bonds between Cα and its substituents.
The easily measured α,β-elimination of β- c h l o ro -D/L-alanine served to test
for Cαd e p rotonation, which underlies the majority of PLP-dependent re a c-
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Fig. 3. Competition ELISA of antibodies for aldimine binding. The Schiff base 3 w a s
formed from PLP in the presence of D- or L-norleucine or glycine. The assay measure s
the binding of the antibodies to the antigen 8 (s e e Fig. 2) in the absence and pre s e n c e
of PLP 1 or of PLP and amino acid 2, which react nonenzymically to form the Schiff
base 3. For antibodies 13B10, 15A9, 11C2, 6E9, and 5G12, the concentration of PLP w a s
100 µM; for 8H4 and 14G1, it was 1 and 2 mM, re s p e c t i v e l y. The amino-acid concen-
tration was 25 mM. These conditions ensured that at least 80% of the cofactor in the
incubation mixture was present as Schiff base. In all cases, inhibition of antibody-
antigen binding by the amino acids alone was negligible.
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tions of amino acids. Owing to its good leaving group in the β p o s i t i o n ,
this substrate analog is decomposed to chloride, ammonia, and re a d i l y
detectable pyruvate in an α,β-elimination reaction that is initiated by depro-
tonation of Cα ( 11 ). β- C h l o roalanine thus allows a convenient and almost
universal screening for deprotonation at Cα, which is an integral step in
most PLP-dependent reactions of amino acids ( 1 ). Antibody 13B10 was
found to catalyze the α,β-elimination of β- c h l o ro -L-alanine, which is con-
sistent with its enantiomeric binding specificity. In contrast, antibody 15A9,
which preferably binds the aldimine with L-amino acids (s e e Fig. 3), cat-
alyzed exclusively the reaction of β- c h l o ro -D-alanine. A p p a re n t l y, the
Cα-H bond of the L-amino-acid substrate is directed toward an inert sur-
face region of the antibody. The more catalytically active antibody 15A9
was chosen for further exploration.
T h ree reactions were found to be catalyzed by antibody 15A9: for-
mation of aldimine, deprotonation at Cα as reflected by α,β- e l i m i n a t i o n
of β- c h l o roalanine, and transamination with hydrophobic D-amino acids
(s e e Table 1). Catalysis of aldimine formation might reflect a favorable re l-
ative orientation of bound PLP and amino acid. α,β-Elimination of
β- c h l o roalanine and transamination share one important feature: the cru-
cial reaction steps are proton transfers (s e e Fig. 1). A p p a re n t l y, in antibody
13B10 and 15A9 acid-base groups are positioned in proximity of Cα a n d
Cα/ C 4′, re s p e c t i v e l y. A l t e r n a t i v e l y, water molecules might have access to
these atoms and mediate the proton transfers. With antibody 15A9, transam-
ination is two orders of magnitude slower than α,β-elimination, suggest-
ing that re p rotonation at C4′ is rate-limiting. Antibody 15A9 was also found
to catalyze the stereoselective exchange of the α- p rotons of glycine ( 1 2 ).
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Table 1
Kinetic Parameters for the Reactions Catalyzed by Antibody 15A9a
k′cat K′m
Reaction Substrate(s) (min–1) (mM)
α,β-Eliminationb β-Chloro-D-alanine 50.42 10
Transamination D-Alanine + PLP 10.42 25
Transamination Pyruvate + PMP 10.11 19
Transaminationc D-Norleucine + PLP 10.07 25
aThe K′m values refer to the amino acids and pyruvate. The concentration of the cofac-
tor was 100 and 200 µM in the reactions with β- c h l o roalanine and the other substrates,
re s p e c t i v e l y. The measurements were performed at pH 7.0 for α,β-elimination and at pH
7.5 for transamination, both at 25°C. The rates were corrected for the rates observed in the
absence of antibody. PMPis used as abbreviation for pyridoxamine-5′-phosphate. For exper-
imental details, s e e ref. 6.
bβ- C h l o ro -L-alanine did not undergo elimination.
cSlower transamination was detected with Nε- a c e t y l -D-lysine, D-lysine, D- t r y p t o p h a n ,
D- t y rosine, and D-histidine as well as in the case of PMP plus 2-oxocapronate. No re a c t i o n
was detectable with L-amino acids.
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Antibody 15A9 is the only antibody found to catalyze the transfor-
mation of a natural amino acid. The antibody is remarkably re a c t i o n - s p e-
cific; transamination is the only observable reaction. The antibody
accelerates the transamination reaction of PLP and an amino acid, and also
in the reverse direction with PMP and a keto acid as substrates. The ori-
entation of the Cα-substituents relative to the plane of the resonance system
of imine and coenzyme together with the presence (and absence) of cat-
alytically effective protein side chains serving as general acid–base gro u p s
or modulating the electron repartition in the coenzyme-substrate adduct
a re thought to determine the reaction specificity in PLP-dependent enzymes
( 1 3 – 1 5 ). In contrast to the reaction specificity, the substrate specificity of
15A9 is less strictly defined—appare n t l y, hydrophobic amino acids and
keto acids in the reverse reaction with PMP a re generally accepted as
s u b s t r a t e s .
N o n p roteinaceous cofactors endow many enzymes with chemical
functions that their protein parts alone cannot provide. The present re s u l t s
show that the combination of a binding-specific antibody with a re a c t i v e
cofactor—even if dissociable—seems a promising approach to extend the
range of reactions that can be catalyzed by antibodies. Cofactor and anti-
body effectively complement each other (s e e Table 2). As in enzymes, the
p rotein enhances the catalytic efficacy of the cofactor and ensures re a c t i o n
s p e c i f i c i t y, stere o s p e c i f i c i t y, and substrate specificity. In the earliest attempt
to generate catalytically active antibodies, a polyclonal antiserum against
the reduced Schiff base formed from PLP and 3′- a m i n o -L- t y rosine was pre-
p a red. The antibodies were found to bind the amino acid PLP and their
aldimine adduct. In comparison to PLP alone, they brought about a five
Applied Biochemistry and Biotechnology Vol. 83, 2000
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Table 2
Rate Acceleration by PLP and Catalytic Antibody 15A9 (Ab)a
Relative rate
Reaction Reactive species constants
α,β-Elimination β-Chloro-D-alanine 1
Aldimine [β-chloro-D-alanine-PLP] 104
[β-Chloro-D-alanine-PLP] · Ab 2 × 107
Transamination Aldimine [D-alanine-PLP] 1
[D-Alanine-PLP] · Ab 5 × 103
D-Norleucine plus pyruvate 1
D-Alanine plus PLP 104
aFor both α,β-elimination and transamination, the first-order rate constants of the re a c-
tions of the indicated species are compared. All rates were measured at 25°C with the excep-
tion of those of D-norleucine and pyruvate. The two entries at the bottom of the table serve
to estimate the contribution of PLP to catalysis of the transamination reaction; the second-
o rder rate of the production of alanine from pyruvate and an amino acid is compared with
the second-order rate of the reaction of PLP with an amino acid. For experimental details,
s e e ref. 6.
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times enhanced rate of α- p roton exchange of L- t y rosine ( 1 6 ). A M A b ,
generated against the reduced aldimine of pyridoxal and 4′- n i t ro -
L-phenylalanine, accelerated aldimine formation between 5′- d e o x y p y r i-
doxal and 4′- n i t ro -D-phenylalanine. However, the antibody did not pro-
mote any further reactions characteristic of pyridoxal catalysis ( 1 7 ).
The success of the approach described here seems to be a result of the
s c reening protocol. Its selection criteria were the formation of the planar
resonance system of the external aldmine and catalysis of depro t o n a t i o n
at Cα. The successive screening steps plausibly simulate the functional
selection pre s s u res that probably have been operative in the molecular
evolution of protein-assisted pyridoxal catalysis. The similarity is also evi-
dent in the development of specificity. In the evolution of PLP-dependent
enzymes, specialization for reaction specificity clearly preceded that for
substrate specificity ( 2 , 1 8 ). The analogy reflects the interplay of chance and
n e c e s s i t y, which is at work in both cases.
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Discussion
S c h o w e n: Do you get both phases of the reaction? Do you get the re g e n e r a t i o n —
the ping and the pong?
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C h r i s t e n: Yes. The antibody catalyzes the reaction between pyridoxal phos-
phate and pyrvate.
S c h o w e n: And do you know yet if it is stereospecific? Do you get the
L-amino acids?
C h r i s t e n: It is specific for D-amino acids, which is unexpected, because the
hapten was an L-amino acid, and the good binders are L-amino acids. But
the only reaction we could observe was with D-amino acids, in particular
with the alanine. Our interpretation is that, with L-amino acids, the
Cα- h y d rogen bond points toward some inert part of the antibody. Wi t h
like L-alanine, the CH bond acts as a proton donor to a group of the anti-
b o d y, or it is just a base in the solvent that is mediating the depro t o n a t i o n .
P a u l: Could you comment on the transition state-like features of the hapten
vs the ground-state features? Which one in your opinion might contribute
m o re towards the generation of catalysis?
C h r i s t e n: I think that our hapten is not a transition-state analog. It is an
analog of a reaction intermediate, which has a finite lifetime and can be
observed spectro s c o p i c a l l y. A transition-state is something much more
t r a n s i t o r y.
P a u l: I was struck by the evolutionary scheme you showed. I think you
said that catalysis came first and substrate binding came later in evolu-
tion. Assuming that catalysis is more difficult than simple binding, do you
consider your scheme to be an exception to the normal evolutionary ru l e s
that we have learned?
C h r i s t e n: No, I think this is the truth. The notion that catalysis isn’t more
d i fficult but is just more important in evolution is probably correct. It could
be both.
S e l a: Yo u ’ re really saying the chemistry came first, not the exact stru c t u re
of the compound as it is today.
C h r i s t e n: It’s conceivable that over the course of evolution, a substrate
binding site was developed first, in this case the tyrosine-binding site, and
then there was divergence of the sequence along with specialization for
catalysis of diff e rent reactions, transamination, or decarboxylation, and so
on. But this is not what happened. First, there was actually specialization
of the primordial enzyme for catalysis with a particular reaction speci-
ficity—say alpha-decarboxylation or transamination. Then, in the last step
of specialization and divergence, there evolved the development of sub-
strate specificity.
G o l o l o b o v: At a certain stage of the reaction you may lose the stere o i s o m e r
configuration because you deprotonate the Cα atom. Since you said the
reaction is D-amino-acid specific, what is the configuration of product? Is
it still D or do you also get the L f o r m ?
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C h r i s t e n: The product is achiral. We can’t say.
G re e n: I think being able to put in cofactors is a very important dire c t i o n .
Almost all of the transition-state analog-based catalytic antibodies do not
use any cofactors, whereas enzymes certainly do. A few comments and
questions. Since you used the reduced compound, maybe it is not so sur-
prising that the antibody happens to choose a chirality that is specific for
the D compound. Concerning evolution, have you thought about comple-
mentation—that is, putting this antibody into some species that lacks the
enzyme and trying to see whether it could evolve a superior-rate constant,
as has been done antibody with a chorismatic mutase in yeast? Have you
thought about immunogens that are improved intermediate analogs, or as
you said, transition analogs—for example, instead of the carbon–nitro g e n
single bond, maybe a carbon–carbon double bond or a nitro g e n – n i t ro g e n
double bond to get the planar geometry?
C h r i s t e n: R e g a rding the first question, metabolic screening is a possibil-
i t y, but there are major hurdles learned from unencouraging experiences
in another case. We thought it is better to stick to what we have and first
determine its stru c t u re. Our efforts are now focused to get the stru c t u re of
this antibody. On the basis of this stru c t u re—which we hope we will get—
we will see how we can improve this antibody.
N e u b e rg e r: You said binding evolved before catalysis, because you got the
transaminases in one family and the decarboxylases in a sibling family—
t h e y ’ re cousins. I don’t see how you can know that a transaminase didn’t
evolve all the transaminases, and then one of the transaminase evolved to
the decarboxylases. It seems the only reason you say that they are cousins
rather than children is because you cannot see close relationship between
the decarboxylases and one individual of the transaminase family. But that
does not seem to me sufficient to say that the two catalysts evolved par-
allel to each other rather than in a sequential ord e r.
C h r i s t e n: T h e re might be a misunderstanding. I said the second step was
the specialization for substrate specificity. Of course, there had to be bind-
ing of amino acids—there had to be a recognition site, for an α- d e c a r-
boxylase and the α-amino group. Amino acids certainly also had to bind
to this unspecific ancestor enzyme. Your direct question, as I understood
it, was how we grouped the transaminases and the decarboxylases. A l l
t h ree transaminases are structurally more similar with each other than they
a re with any of the decarboxylases.
N e u b e rg e r: But what if one of the transaminases has evolved further to
become a decarboxylase?
C h r i s t e n: The decarboxylases could be the children of a very ancient tran-
saminase; that is possible. We just have the modern stru c t u res, of course,
and we find that all decarboxylases belong to one subfamily and all transam-
inases to another subfamily.
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S c h o w e n: On the question of transition-state vs intermediate analogs, I am
ready to be corrected, but I think in all patents claiming to generate
catalytic antibodies, the antigens have been intermediate analogs, not
transition-state analogs.
Tr a m o n t a n o: I would go one step beyond that. I propose that all so-called
transition-state analogs are simply electrostatic molecules engulfed in some
deep pocket in the antibody, and that the electrostatic interactions within
the pocket are used for catalysis. Have you considered whether doing the
same experiment with a neutral molecule such as the one Buddy Gre e n
suggested will give you a diff e rent re s u l t ?
C h r i s t e n: We had this idea that the special two-step screening is impor-
tant, which is why we followed this route. Your suggestion is certainly a
p o s s i b i l i t y.
S e l a: Do you have the primary stru c t u re of this abzyme?
C h r i s t e n: We have the primary stru c t u re, but we do not have a thre e -
dimensional stru c t u re .
S e l a: Have you done some modeling? Is the antibody close to a transam-
inase or a decarboxylase? I understand very well your position on why the
chemistry came first before the protein in this example of catalysis. Yo u
make the appropriate point about proper orientation of the orbitals, and
some chemistry by the antibody is clearly taking place.
P a u l: In view of all of the data, it seems appropriate to remain skeptical
about the basic model of transition-state analog immunization and the ori-
gins of the catalytic activity. While the stru c t u re of the immunogen is clearly
partly ground-state-like and partly transition state-like, the key issue
remains—when you immunize with a so-called transition-state analog, is
the catalytic activity purely accidental, is it due to development of sub-
strate-binding capability combined with some innate tendency toward
catalysis, or is there some true advantage to mimicking the transition-state-
like features? It is valid to question the basic premise re g a rdless of the elec-
tostatic or orbital steering mechanism of antibody–antigen interactions.
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